AdAlta and Oktopi partner to bring human guided AI into drug development decisions

Latest News

AdAlta (ASX:1AD) has announced a strategic collaboration with Oktopi to access its software-as-a-service knowledge system designed to sharpen medicine development decisions.

Oktopi is a human-guided platform built on AWS Bedrock. AdAlta said the platform will support its research teams to plan work, identify the most important questions at each stage of development, and spot gaps before they cause costly delays.

The collaboration builds on AdAlta’s in-house AI work, including EMU, an AI agent built on Anthropic’s Claude that pre-screens new in-licensing opportunities for the company’s East-to-West strategy.

AdAlta expects the combined tools to speed decision making, reduce risk, improve the quality of research plans and regulatory documents, and make consultant use more efficient as the business scales.

AdAlta Consultant Chief Medical Officer Dr Kevin Lynch said, "This collaboration is tremendously exciting for AdAlta. Being able to rapidly pressure-test our development plans — effectively having a broad committee of senior experts available on demand — is enormously powerful, especially at the first-in-human stage, where we must be sure we are asking the right questions and addressing critical gaps before committing to major investment. It will also help us get the best value from our specialist consultants. Combined with our in-house, Claude-based screening agent, AI is becoming a genuine competitive advantage in how we plan our research and choose the products that can most help patients facing fatal diseases."

Oktopi Co-Founder and CEO Dr Craig Rayner AM said, "We built Oktopi so that small, expert teams can pressure test their development plans with the rigour of a full expert committee, on demand and on every program. AdAlta is exactly the kind of disciplined, science-led developer the platform is built for, and we are delighted to support its East to West strategy. Pairing Oktopi with AdAlta’s own Claude based screening agent shows how AI, kept firmly under expert control, can improve both the selection of assets and the decisions that shape their development."